Bristol-Myers Squibb gets rated a hold, as I see future value in its clinical portfolio and pipeline, particularly ...

We recently compiled a list of the 12 Best Long Term Low Risk Stocks to Buy Right Now. In this article, we are going to take ...

In an amicus brief, several advocacy groups warned that letting the lawsuit proceed past a motion to dismiss could open the ...

Bristol-Myers Squibb Company (BMY) is one of the leading biopharmaceutical companies focused on developing treatments for ...

The new product will help Bristol Myers Squibb compete with biosimilars as Opdivo faces looming patent expiration. Sotyktu, which became the first TYK2 inhibitor to reach the market after its 2022 ...

Bristol Myers Squibb believes Alzheimer's treatment is the largest potential market for its newly approved schizophrenia drug, Cobenfy, which it expects to eventually generate billions of dollars ...

Analyst Terence Flynn of Morgan Stanley maintained a Sell rating on Bristol-Myers Squibb (BMY – Research Report), retaining the price target of ...

Leerink Partners analyst David Risinger has reiterated their bullish stance on BMY stock, giving a Buy rating on January 12.Invest with ...

Financial giants have made a conspicuous bullish move on Bristol-Myers Squibb. Our analysis of options history for Bristol-Myers Squibb BMY revealed 10 unusual trades. Delving into the details ...

Shares of Bristol Myers Squibb Co. BMY shed 3.04% to $58.76 Tuesday, on what proved to be an all-around positive trading ...

In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against the other dividend stocks. Dividend stocks, while popular among investors, have been ...